LDOS — Leidos Holdings, Inc.

Leidos Holdings, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $4.2 billion, down 3.6% year-over-year; adjusted for a six-week government shutdown and an extra week in Q4 2024, revenue would have increased approximately 4%.
• Full-Year Revenue: $17.2 billion, up 3.1%.
• Adjusted EBITDA Margin: 14.1% for the year, a 120 basis point increase; Q4 margin at 13.2%, up 160 basis points year-over-year.
• Non-GAAP Diluted EPS: $2.76 for Q4 and $11.99 for the year, reflecting a 17% increase.
• Free Cash Flow: $452 million for Q4, $1.63 billion for the year, representing a 104% conversion rate.

2. Strategic Updates and Business Highlights

• Net Bookings: $5.6 billion in Q4, maintaining a book-to-bill ratio of 1.3.
• Key Contracts: Awarded a $2.2 billion contract for Air Force radar systems and a $455 million contract for cloud services.
• Acquisitions: Acquired Kudu Dynamics for cyber capabilities and announced plans to acquire Entrust Solutions Group for $2.4 billion to enhance energy engineering services.
• Investment in Innovation: $312 million invested in internal research and development (IRAD) and capital expenditures in 2025, with plans to triple CapEx to $350 million in 2026.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $17.5 billion and $17.9 billion, indicating up to 4% growth.
• Adjusted EBITDA Margin: Projected mid-13% for 2026, normalizing from one-time benefits in 2025.
• Non-GAAP Diluted EPS Guidance: Between $12.05 and $12.45.
• Operating Cash Flow: Expected to remain robust at $1.75 billion, despite a headwind from Section 174 timing.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline in Q4: The 3.6% decrease in Q4 revenue raises concerns about immediate growth, particularly given the impact of the government shutdown.
• Transition Challenges: The Managed Health Services segment faced volume challenges, particularly with the transition of electronic health records, which may affect future performance.
• Competitive Pressures: Concerns regarding potential price competition driven by AI advancements in the software sector and the impact of new entrants in the health services market.

5. Notable Q&A Insights

• Investment Focus: Management emphasized that CapEx will support growth across multiple sectors, including defense and health, with ongoing negotiations for co-investment opportunities with the Department of Defense.
• Growth Trajectory: Analysts noted expectations for slower growth in the early part of 2026, with acceleration anticipated in the second half due to new program wins and a robust pipeline.
• Recompete Strategy: The company remains confident in its ability to retain contracts, particularly in the health sector, despite increased competition.
• AI as an Opportunity: Management views AI as a force multiplier rather than a threat, aiming to leverage it to enhance operational efficiency and customer solutions.

Overall, Leidos demonstrated resilience in 2025 despite external challenges, with a strong focus on strategic growth areas and a positive outlook for 2026, albeit with some caution regarding potential headwinds.